

12-10-01  
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

A

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>Only for new nonprovisional applications under 37 C.F.R. 1.53(b))</small>		Attorney Docket No. 2825.2025-001			
		First Named Inventor or Application Identifier Stacey Bolk			
		Express Mail Label No. EV052027940US			
Title of Invention Association of Thrombospondin Polymorphisms with Vascular Disease					
<b>APPLICATION ELEMENTS</b> See MPEP chapter 600 concerning utility patent application contents.		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231			
<p>1. <input type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification <b>[Total Pages 34]</b> (preferred arrangement set forth below)</p> <ul style="list-style-type: none"> <li>- Descriptive title of the invention</li> <li>- Cross References to Related Applications</li> <li>- Statement Regarding Fed sponsored R &amp; D</li> <li>- Reference to microfiche Appendix</li> <li>- Background of the Invention</li> <li>- Summary of the Invention</li> <li>- Brief Description of the Drawings</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul> <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) <b>[Total Sheets 5]</b>  <input checked="" type="checkbox"/> Formal      <input type="checkbox"/> Informal  <input type="checkbox"/> Fig. of the Drawings for Publication    <input type="checkbox"/></p> <p>4. <input type="checkbox"/> Oath or Declaration/POA <b>[Total Pages [ ] ]</b> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Newly executed (original or copy)</li> <li>b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. 1.63(d)) (for continuation/divisional with Box 18 completed) <b>[NOTE Box 5 below]</b> <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).</li> </ul> </li> </ul> </p> <p>5. <input type="checkbox"/> Incorporation By Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>					
<p>6. <input type="checkbox"/> Microfiche Computer Program (<i>Appendix</i>)</p> <p>7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)       <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Computer Readable Copy</li> <li>b. <input type="checkbox"/> Paper Copy (identical to computer copy) <b>[ ] Pages</b></li> <li>c. <input type="checkbox"/> Statement verifying identity of above copies</li> </ul> </p>					
<b>ACCOMPANYING APPLICATION PARTS</b>					
<p>8. <input type="checkbox"/> Assignment Papers (cover sheet &amp; documents)  <input type="checkbox"/> Assignee -</p> <p>9. <input type="checkbox"/> 37 C.F.R. 3.73(b) Statement    <input type="checkbox"/> Power of Attorney</p> <p>10. <input type="checkbox"/> English Translation Document (<i>if applicable</i>)</p> <p>11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449    <input type="checkbox"/> Copies of IDS Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)</p> <p>14. <input type="checkbox"/> Small Entity Statement(s)    <input type="checkbox"/> Statement filed in prior application, status still proper and desired</p> <p>15a. <input type="checkbox"/> Foreign Priority Claim under 35 U.S.C. §119(a)-(b)</p> <p>15b. <input type="checkbox"/> Certified Copy of Priority Document(s)</p> <p>16. <input checked="" type="checkbox"/> Nonpublication Request (<i>check parent application</i>)</p> <p>17. <input type="checkbox"/> Other: _____</p>					
<p>18. If a <b>CONTINUING APPLICATION</b>, check appropriate box and supply the requisite information:  <input type="checkbox"/> Continuation    <input type="checkbox"/> Divisional    <input type="checkbox"/> Continuation-in-part (CIP)    of prior application No.: _____</p> <p>Prior application information:    Examiner: _____    Group Art Unit: _____</p>					
<b>19. CORRESPONDENCE ADDRESS</b>					
NAME	Lisa M. Treannie, Esq. HAMILTON, BROOK, SMITH & REYNOLDS, P.C.				
ADDRESS	530 Virginia Road, P.O. Box 9133				
CITY	Concord	STATE	MA	ZIP CODE	01742-9133
COUNTRY	USA	TELEPHONE	(978) 341-0036	FAX	(978) 341-0136

Signature	Pamela A. Torpey	Date	November 13, 2001
Submitted by Typed or Printed Name	Pamela A. Torpey	Reg. Number	45,736

# HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

<b>NONPUBLICATION REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)</b>	First Named Inventor	Stacey Bolk
	Attorney Docket No.	2825.2025-001
	Express Mail Label No.	EV052027940US
Title of Invention	Association of Thrombospondin Polymorphisms with Vascular Disease	

Pursuant to 37 C.F.R. § 1.213(a)(3), I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

The undersigned is an agent for applicants.

November 13, 2001  
Date

Pamela A. Torpey

Pamela A. Torpey  
Registration No. 45,736  
Telephone No. (978) 341-0036  
Facsimile No. (978) 341-0136

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after that date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**